Confluence Investment Management LLC boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 199,252 shares of the company’s stock after buying an additional 4,190 shares during the period. Confluence Investment Management LLC owned approximately 0.05% of Thermo Fisher Scientific worth $31,693,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Bank of Montreal Can bought a new position in shares of Thermo Fisher Scientific during the second quarter valued at $32,053,000. Carmignac Gestion raised its position in shares of Thermo Fisher Scientific by 23.3% in the second quarter. Carmignac Gestion now owns 4,046,550 shares of the company’s stock valued at $597,918,000 after buying an additional 763,421 shares during the last quarter. Evercore Wealth Management LLC raised its position in shares of Thermo Fisher Scientific by 6.0% in the second quarter. Evercore Wealth Management LLC now owns 281,316 shares of the company’s stock valued at $41,568,000 after buying an additional 15,849 shares during the last quarter. First Pacific Advisors LLC raised its position in shares of Thermo Fisher Scientific by 5.9% in the second quarter. First Pacific Advisors LLC now owns 1,788,830 shares of the company’s stock valued at $264,318,000 after buying an additional 99,770 shares during the last quarter. Finally, Columbus Circle Investors raised its position in shares of Thermo Fisher Scientific by 363.2% in the second quarter. Columbus Circle Investors now owns 668,109 shares of the company’s stock valued at $98,720,000 after buying an additional 523,867 shares during the last quarter. Institutional investors own 86.28% of the company’s stock.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Thermo Fisher Scientific Inc. (NYSE:TMO) traded down 0.26% during mid-day trading on Tuesday, hitting $139.95. 416,613 shares of the stock were exchanged. The company has a 50-day moving average price of $149.29 and a 200-day moving average price of $151.92. The company has a market cap of $55.28 billion, a P/E ratio of 27.97 and a beta of 1.24. Thermo Fisher Scientific Inc. has a one year low of $119.75 and a one year high of $160.68.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, October 27th. The company reported $2.03 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.97 by $0.06. The business earned $4.49 billion during the quarter, compared to analyst estimates of $4.39 billion. Thermo Fisher Scientific had a return on equity of 14.95% and a net margin of 11.10%. The firm’s revenue was up 8.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.80 EPS. On average, analysts predict that Thermo Fisher Scientific Inc. will post $8.25 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, January 16th. Stockholders of record on Thursday, December 15th will be issued a dividend of $0.15 per share. The ex-dividend date of this dividend is Tuesday, December 13th. This represents a $0.60 annualized dividend and a dividend yield of 0.42%. Thermo Fisher Scientific’s dividend payout ratio is 12.00%.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be viewed at https://www.thecerbatgem.com/2016/11/29/confluence-investment-management-llc-purchases-4190-shares-of-thermo-fisher-scientific-inc-tmo.html.

Several research analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $178.00 price objective on the stock in a report on Monday, August 1st. Bank of America Corp. set a $180.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Friday, October 7th. Jefferies Group reiterated a “hold” rating on shares of Thermo Fisher Scientific in a report on Thursday, August 4th. JPMorgan Chase & Co. assumed coverage on shares of Thermo Fisher Scientific in a report on Thursday, September 22nd. They set an “overweight” rating and a $180.00 price objective on the stock. Finally, Leerink Swann assumed coverage on shares of Thermo Fisher Scientific in a report on Thursday, November 10th. They set an “outperform” rating and a $175.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $164.37.

In other news, CEO Marc N. Casper sold 30,000 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of $151.17, for a total transaction of $4,535,100.00. Following the completion of the sale, the chief executive officer now directly owns 308,647 shares in the company, valued at approximately $46,658,166.99. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 28,797 shares of Thermo Fisher Scientific stock in a transaction dated Friday, September 2nd. The shares were sold at an average price of $151.01, for a total value of $4,348,634.97. Following the sale, the chief executive officer now owns 307,444 shares of the company’s stock, valued at $46,427,118.44. The disclosure for this sale can be found here. Insiders own 0.52% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

5 Day Chart for NYSE:TMO

Receive News & Stock Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related stocks with our FREE daily email newsletter.